Novel glp-1 derivatives

A technology for albumin and compounds, applied in the field of albumin-binding derivatives of therapeutic peptides

Active Publication Date: 2006-11-22
NOVO NORDISK AS
View PDF7 Cites 41 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this high variability in the plasma half-life of peptides, proteins, or other compounds is not fully understood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel glp-1 derivatives
  • Novel glp-1 derivatives
  • Novel glp-1 derivatives

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0564] N ε37 -(2-(2-(2-(Dodecylamino)ethoxy)ethoxy)acetyl)-[Aib 8，22，35 Lys 37 ]GLP-1(7-37)amide

[0565]

[0566] The initial sequence was generated using the resin (Rink amide, 0.68 mmol / g, Novabiochem, 0.25 mmole) on an ABI433A machine following the manufacturer's instructions. All protecting groups are acid labile with the exception of the residue used at position 37 (Fmoc-Lys(ivDde)-OH, Novabiochem), allowing specificity for this lysine but not any other lysine. off protection.

[0567] process

[0568] The resin (0.25 mmole) containing the GLP-1 analog amino acid sequence prepared above was placed in a manual shaker / filter device, and was treated with 2% hydrazine dissolved in N-methylpyrrolidone (2×20ml, 2×12min ) to remove the DDE group, followed by washing with N-methylpyrrolidone (4×20 ml). Fmoc-8-amino-3,6-dioxoctanoic acid (Neosystem FA03202) (4 molar equivalents relative to the resin) was dissolved in N-methylpyrrolidone / dichloromethane (1:1, 20 ml). Hyd...

Embodiment 2

[0573] N ε37 -(2-(2-(2-(17-Sulfohexadecanoylamino)ethoxy)ethoxy)acetyl)-[Aib 8，22，35 , Lys 37 ]GLP-1(7-37)amide

[0574]

[0575] Compounds were prepared according to the methods in Example 1 and "General Synthetic Methods".

[0576] HPLC: (Method A1): RT=45.5min

[0577] LCMS: m / z=792.9 (M+5H) 5+ ,990.9(M+4H) 4+ , 1320.9(M+3H) 3+ , Calculated (M+H) + =3959.9

Embodiment 3

[0579] N ε37 -{2-[2-(2-(15-Carboxypentadecanoylamino)ethoxy)ethoxy]acetyl}-[Aib 8，22，35 , Lys 37 ]GLP-1(7-37)amide

[0580]

[0581] Compounds were prepared according to the methods in Example 1 and "General Synthetic Methods".

[0582] HPLC: (Method B1): RT=43.8min

[0583] HPLC: (Method A1): RT=42.0min

[0584] LCMS: m / z=978.3 (M+4H) 4+ , 1303.8(M+3H) 3+ , Calculated (M+H) + =3909.6

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
affinityaaaaaaaaaa
Login to view more

Abstract

Novel polypeptide derivatives having protracted profile of action. The present invention relates to a compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer. The present invention also relates to a compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer that separates the polypeptide and the albumin binding residue with a chemical moiety comprising at least 5 non-hydrogen atoms where 30-50% of these atoms are either N or O. In one embodiment of this invention the spacer is defined as -(CH2)lD[(CH2)nE]m(CH2)pQq-, wherein l, m and n independently are 1-20 and p is 0-10, Q is -Z-(CH2)lD[(CH2)nG]m(CH2)p-, q is an integer in the range from 0 to 5, each D, E and G independently are selected from -O-, NR<3>-, -N(COR<4>)-, -PR<5>(O)-, and -P(OR<6>)(O)-, wherein R<3>, R<4>, R<5>, and R<6> independently represent hydrogen or C1-6-alky, Z is selected from -C(O)NH-, -C(O)NHCH2-, -OC(O)NH-, -C(O)NHCH2CH2-, -C(O)CH2-, -C(O)CH=CH-, -(CH2)s-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or 1.

Description

field of invention [0001] The present invention relates to novel derivatives of glucagon-like polypeptide-1 (GLP-1) and fragments thereof, analogs of these fragments having protracted action properties, and methods of producing and using them. The present invention also relates to novel derivatives of exendin and uses thereof. Background of the invention [0002] Peptides are widely used in medical practice, and since they can be produced by recombinant DNA techniques, their importance is expected to increase in the coming years. When natural peptides or their analogs are used therapeutically, they are generally found to have higher clearance. In cases where it is desired to maintain high blood levels of a therapeutic agent for an extended period of time, high clearance is inconvenient because of the need for repeated administrations. Examples of peptides with high clearance are ACTH, corticotropin releasing factor, angiotensin, calcitonin, insulin, g...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/62
Inventor J·劳T·K·汉森K·马德森P·布罗奇F·Z·迪尔沃德N·L·乔安森
Owner NOVO NORDISK AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap